天津科学技术出版社

造血干细胞基因编辑与基因治疗:从底层技术开发到临床转化

张旭月 1,2 #,宋宇琦 1,2 #,饶书权 1,2,姚瑶 1,2 *
作者信息
  1. 1 中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020
  2. 2 天津医学健康研究院,天津 301600
#共同第一作者
*通信作者

摘要

造血干细胞(HSC)具有自我更新和多系分化能力,是基因治疗的理想载体。以成簇规律间隔短回文重复序列(CRISPR) -CRISPR 相关蛋白 9(Cas9)为代表的基因编辑技术迅猛发展,推动 HSC 基因治疗从基础研究迈入临床实践,为β-地中海贫血、镰状细胞病等遗传性血液病的根治带来希望。 本综述系统梳理了 HSC 基因编辑的发展脉络与最新进展,以及递送系统与体内治疗新突破;总结了在关键血液病模型中的临床前研究证据与转化挑战;概述了已上市疗法及核心临床试验的疗效与安全性数据。 尽管在编辑精准性、递送效率、长期安全性与治疗可及性方面仍存挑战,但随着新编辑和递送体系的开发、人工智能的辅助以及全球化临床协作的推进,HSC 基因治疗正朝着更安全、高效、可及的精准治愈时代迈进。

Therapeutic gene editing and gene therapy of hematopoietic stem cell: from underlying technology development to clinical translation

Xuyue ZHANG 1,2 #, Yuqi SONG 1,2 #, Shuquan RAO 1,2, Yao YAO 1,2 *
Author Information
  1. 1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
  2. 2 Tianjin Institutes of Health Science, Tianjin 301600, China
#Co-first author
*Corresponding author

Abstract

Hematopoietic stem cells (HSC) possess self-renewal capacity and multilineage differentiation potential, rendering them ideal vehicles for gene therapy. Gene editing technologies exemplified by clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) have advanced rapidly, propelling HSC-based gene therapy from basic research to clinical practice and offering hope for the radical cure of hereditary hematological disorders such as 茁-thalassemia and sickle cell disease. This review systematically summarizes the developmental context and latest advances in HSC gene editing, as well as novel breakthroughs in delivery systems and in vivo therapy;synthesizes preclinical evidence and translational challenges in key hematological disease models; and outlines the efficacy and safety profiles of approved therapies and pivotal clinical trials. Despite lingering challenges in editing precision, delivery efficiency, long-term safety, and treatment accessibility, the development of novel editing and delivery systems, the aid of artificial intelligence, and the progress of global clinical collaboration are driving HSC-based gene therapy toward an era of safer, more efficient, and accessible precision cure.

利益冲突:作者均声明无利益冲突

再生医学研究 Copyright © 2026. All Rights Reserved